Name: BIOFRONTERA INC (BFRI) Stock
Brand: BIOFRONTERA INC
Rating: 4 (3 reviews)

BFRI Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Biofrontera Inc.

Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update

6 days ago - By: Benzinga - Mentions: GWRS IMRX DYAI LEGN ...

Earnings Scheduled For November 12, 2025

7 days ago - By: Benzinga

Biofrontera Earnings Preview

8 days ago - By: Zacks Investment Research - Mentions: ROIV

Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates

11 days ago - By: Biofrontera Inc.

Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M

12 days ago - By: Zacks Investment Research - Mentions: LFCR

Lifecore Biomedical (LFCR) Reports Q1 Loss, Beats Revenue Estimates

12 days ago - By: Biofrontera Inc.

Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025

13 days ago - By: Zacks Investment Research - Mentions: VRDN

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates

14 days ago - By: Zacks Investment Research - Mentions: PTCT

PTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates

a month ago - By: Biofrontera Inc.

Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG

2 months ago - By: Biofrontera Inc.

Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

2 months ago - By: Biofrontera Inc.

Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program

2 months ago - By: Biofrontera Inc.

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk

3 months ago - By: Biofrontera Inc.

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

3 months ago - By: The Motley Fool

Biofrontera Q2 Revenue Jumps 15%

3 months ago - By: The Motley Fool

Biofrontera Revenue Jumps 15% in Q2

3 months ago - By: Biofrontera Inc.

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

3 months ago - By: Zacks Investment Research - Mentions: LCTX

Lineage Cell (LCTX) Reports Q2 Loss, Beats Revenue Estimates

3 months ago - By: Biofrontera Inc.

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

3 months ago - By: Zacks Investment Research - Mentions: PACB

Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates

3 months ago - By: Zacks Investment Research - Mentions: TARS

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: Biofrontera Inc.

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

5 months ago - By: Biofrontera Inc.

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

6 months ago - By: Biofrontera Inc.

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

6 months ago - By: Biofrontera Inc.

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

6 months ago - By: Biofrontera Inc.

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

6 months ago - By: Zacks Investment Research - Mentions: KYMR

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates

6 months ago - By: Zacks Investment Research - Mentions: NTLA

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

7 months ago - By: ACCESS Newswire

Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025

7 months ago - By: Biofrontera Inc.

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis

8 months ago - By: Biofrontera Inc.

BIOFRONTERA INC (BFRI) Stock News

BFRI Latest News, Press Relases and Analysis

Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update

Earnings Scheduled For November 12, 2025

Biofrontera Earnings Preview

Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates

Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M

Lifecore Biomedical (LFCR) Reports Q1 Loss, Beats Revenue Estimates

Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates

PTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates

Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG

Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Biofrontera Q2 Revenue Jumps 15%

Biofrontera Revenue Jumps 15% in Q2

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Lineage Cell (LCTX) Reports Q2 Loss, Beats Revenue Estimates

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update